Hafiz Muhammad Ishaq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hafiz Muhammad Ishaq has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Imran Shair Mohammad
Department of Radiology, City of Hope Medical Center, Duarte, CA 91010, USA
2 shared publications - Anup Kumar Patel
Department of Radiology, City of Hope National Medical Center, 1500 East Duarte Rd., Duarte, California 91010, USAhttps://ror.org/00w6g5w60https://www.isni.org/isni
1 shared publication - Cansu Umran Tunc
Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, USA
1 shared publication - Dilek Kanarya
Nanothera Lab, Drug Application and Research Center (ERFARMA), Erciyes University, 38039, Kayseri, Turkeyhttps://ror.org/047g8vk19https://www.isni.org/isni
1 shared publication Fatima Rasool
University College of Pharmacy, University of the Punjab, Lahore, Pakistan
1 shared publication- Gaoping Qin
Shaanxi Provincial People's Hospital, China
1 shared publication
Latest Publications
- Open Access
- 5 August 2025
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 16 (1) , 1246-1276
Better together: biomimetic nanomedicines for high performance tumor therapy
The emergence of nanotechnology offers a promising avenue for enhancing cancer treatment outcomes. In this context, biomimetic nanoparticles have emerged as an exciting frontier in the field of biomedicine. These nanoparticles can emulate essential biological functions, drawing from an abundant reservoir of cellular capabilities. This includes engaging in biological binding, precise homing to tumor sites, and interaction with immune cells. These inherent traits endow biomimetic nanoparticles with a suite of intelligent features, including biocompatibility, low immunogenicity, reduced toxicity, immune evasion, prolonged circulation, homotypic binding, enhanced tumor targeting, and the capability of precise delivery. By integrating biologically inspired coatings derived from cell membranes with nanoparticle cores, these carriers become highly versatile vessels for encapsulating a wide array of therapeutic agents. As a result, they are being extensively harnessed for the precise delivery of drugs and genes, underpinning numerous biomedical applications. This discussion delves into the challenges and opportunities presented by biomimetic nanoparticles and offers a comprehensive exploration of their fundamentals and recent breakthroughs, with an eye towards clinical translation. By bridging the gap between scientific innovation and clinical utility, biomimetic nanoparticles hold great promise for advancing the field of cancer treatment.
- 5 August 2025
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 16 (1) , 1246-1276
Open AccessBetter together: biomimetic nanomedicines for high performance tumor therapy
The emergence of nanotechnology offers a promising avenue for enhancing cancer treatment outcomes. In this context, biomimetic nanoparticles have emerged as an exciting frontier in the field of biomedicine. These nanoparticles can emulate essential biological functions, drawing from an abundant reservoir of cellular capabilities. This includes engaging in biological binding, precise homing to tumor sites, and interaction with immune cells. These inherent traits endow biomimetic nanoparticles with a suite of intelligent features, including biocompatibility, low immunogenicity, reduced toxicity, immune evasion, prolonged circulation, homotypic binding, enhanced tumor targeting, and the capability of precise delivery. By integrating biologically inspired coatings derived from cell membranes with nanoparticle cores, these carriers become highly versatile vessels for encapsulating a wide array of therapeutic agents. As a result, they are being extensively harnessed for the precise delivery of drugs and genes, underpinning numerous biomedical applications. This discussion delves into the challenges and opportunities presented by biomimetic nanoparticles and offers a comprehensive exploration of their fundamentals and recent breakthroughs, with an eye towards clinical translation. By bridging the gap between scientific innovation and clinical utility, biomimetic nanoparticles hold great promise for advancing the field of cancer treatment.
- 15 November 2022
- Published by Elsevier in Microbial Pathogenesis
- Vol. 173 (Pt A) , 105886
Axillary fossaa microbial dysbiosis and its relationship with axillary osmidrosis patients
- 15 November 2022
- Published by Elsevier in Microbial Pathogenesis
- Vol. 173 (Pt A) , 105886
Axillary fossaa microbial dysbiosis and its relationship with axillary osmidrosis patients
- 1 November 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 107, 806-817
Phytocosmeceutical formulation development, characterization and its in-vivo investigations
- 1 November 2018
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 107, 806-817
Phytocosmeceutical formulation development, characterization and its in-vivo investigations